JAK Inhibitors for the Treatment of Inflammatory Bowel Disease

Authors

  • Christopher Ma, MD, MPH, FRCPC Division of Gastroenterology & Hepatology, University of Calgary; Department of Community Health Sciences, University of Calgary; Alimentiv Inc., London, ON

DOI:

https://doi.org/10.58931/cibdt.2023.115

Keywords:

JAK inhibitors, inflammatory bowel disease

Abstract

Over the past decade, Janus kinase (JAK) inhibitors have been developed for the treatment of several immune-mediated inflammatory diseases, including ulcerative colitis (UC) and Crohn’s disease (CD). The JAK-signal transducer and activator of transcription (STAT) pathway plays an essential role in coordinating the human immune response. Phosphorylation and activation of the JAK family of tyrosine kinases results in subsequent activation of intracytoplasmic STAT pathways with upregulation of inflammatory gene transcription. Blocking this signalling results in broad-spectrum immunosuppression, which is effective in the treatment of rheumatoid arthritis (RA), psoriasis, atopic dermatitis, and inflammatory bowel disease (IBD). To date, three oral, small-molecule JAK inhibitors (tofacitinib, filgotinib, and upadacitinib) have received regulatory approval in various jurisdictions globally for the treatment of moderate-to-severely active UC. It is anticipated that upadacitinib will soon become the first novel, advanced oral small molecule therapy approved for moderate-to-severely active CD. While these agents are highly effective, emerging data has highlighted potentially relevant safety signals associated with JAK inhibitors, and that the therapeutic index of these therapies may be distinct from that of monoclonal antibodies. Therefore, JAK inhibitors have a unique position in the therapeutic armamentarium for IBD. Here, we summarize the evidence supporting the use of JAK inhibitors and provide an overview of their practical applications in clinical care.

Author Biography

Christopher Ma, MD, MPH, FRCPC, Division of Gastroenterology & Hepatology, University of Calgary; Department of Community Health Sciences, University of Calgary; Alimentiv Inc., London, ON

Christopher Ma is an academic gastroenterologist at the University of Calgary. He has advanced training in inflammatory bowel disease, clinical trial design, and analytic research methods. He has published over 170 peer-reviewed manuscripts and received over $6.5 million in research grant funding. His clinical and research focus is on patients with advanced Crohn’s disease, ulcerative colitis, and eosinophilic esophagitis who require advanced medical therapies.

References

O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70. DOI: https://doi.org/10.1056/NEJMra1202117

Sedano R, Ma C, Jairath V, et al. Janus kinase inhibitors for the management of patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2022;18:14-27.

Ma C, Lee JK, Mitra AR, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:5-23. DOI: https://doi.org/10.1111/apt.15297

Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84. DOI: https://doi.org/10.1021/jm1004286

Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723-36. DOI: https://doi.org/10.1056/NEJMoa1606910

Sandborn WJ, Peyrin-Biroulet L, Sharara AI, et al. Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status. Clin Gastroenterol Hepatol 2022;20:591-601 e8. DOI: https://doi.org/10.1016/j.cgh.2021.02.043

Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative Ccolitis. Clin Gastroenterol Hepatol 2019;17:139-47. DOI: https://doi.org/10.1016/j.cgh.2018.07.009

Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis 2022;28:32-40. DOI: https://doi.org/10.1093/ibd/izab011

Ma C, Panaccione R, Xiao Y, et al. REMIT-UC: Real world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis. Am J Gastroenterol 2022 Dec 8. doi:10.14309/ajg.0000000000002129. Online ahead of print. DOI: https://doi.org/10.14309/ajg.0000000000002129

Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022;399:2113-28. DOI: https://doi.org/10.1016/S0140-6736(22)00581-5

Loftus EV, Jr., Colombel JF, Takeuchi K, et al. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment. Clin Gastroenterol Hepatol 2022 Dec. 1 ;S1542-3565(22)01109-0. doi:10.1016/j.cgh.2022.11.029. Online ahead of print. DOI: https://doi.org/10.1016/j.cgh.2022.11.029

Colombel J-F, Panes J, Lacerda AP, et al. 867f: Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active Crohn’s disease who failed prior biologics: results from a randomized phase 3 U-EXCEED study. Gastroenterology 2022;162:S-1394. DOI: https://doi.org/10.1016/S0016-5085(22)64061-7

Ytterberg SR, Bhatt DL, Connell CA. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. Reply. N Engl J Med 2022;386:1768. DOI: https://doi.org/10.1056/NEJMc2202778

Sandborn, William J., et al. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. Journal of Crohn’s and Colitis (2022).

Sandborn WJ, Panes J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther 2019;50:1068-76. DOI: https://doi.org/10.1111/apt.15514

Burmester, Gerd R., et al. “Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.” RMD open 9.1 (2023):e002735. DOI: https://doi.org/10.1136/rmdopen-2022-002735

Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2022;7:161-170. DOI: https://doi.org/10.1016/S2468-1253(21)00377-0

Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 2021 Dec 22;gutjnl-2021-326390. doi:10.1136/gutjnl-2021-326390. Online ahead of print. DOI: https://doi.org/10.1136/gutjnl-2021-326390

Barberio B, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut 2023 Feb;72(2):264-74. DOI: https://doi.org/10.1136/gutjnl-2022-328052

Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160:1570-83. DOI: https://doi.org/10.1053/j.gastro.2020.12.031

Vermeire S, Su C, Lawendy N, et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the Randomised RIVETING Trial. J Crohns Colitis 2021;15:1130-41. DOI: https://doi.org/10.1093/ecco-jcc/jjaa249

Published

2023-04-11

How to Cite

1.
Ma C. JAK Inhibitors for the Treatment of Inflammatory Bowel Disease . Can IBD Today [Internet]. 2023 Apr. 11 [cited 2024 Oct. 16];1(1):5–10. Available from: https://canadianibdtoday.com/article/view/1-1-1-ma

Issue

Section

Articles